Table 1.
Prices of vaccines produced by R&D and non-R&D producers.
| Vaccine | No. producers |
Price/dose (USD) |
Price/dose (USD) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GAVI vaccines | 2001b | 2014 | UNICEF Supply status 2014a | R&D-producers | 2001b | 2014 | Differenced | Non-R&D producers | 2001b | 2014 | Differenced |
| DTP-HepB-Hib (10 dose vials) | 1 | 3 | Supply > demand | Serum Institute of India | 1.75–2.105 | 1.95–2.105 | +5.2% | ||||
| biological E | — | 1.19 | |||||||||
| Panacea | — | 1.8–1.94 | |||||||||
| DTP-HepB-Hib | 1 | 3 | Supply > demand | Crucell/Berna B Korea | 3.63 | 2.4–2.6 | −31.1% | biological E | — | 2.35 | |
| Serum Institute of India | — | 2.7 | |||||||||
| Human papillomavirus | 2 | 2 | Supply > demand | GSK | 4.6 | 4.6 | 0% | ||||
| Merck | 4.5 | 4.5 | 0% | ||||||||
| Measles (10 dose vials) | 3 | 3 | Limited supply | Sanofi Pasteur | 0.144 | 0.45 | +212% | Serum Institute of India | 0.109 | 0.252 | +131% |
| Eisai Co | 0.125 | — | |||||||||
| PT Biofarma | — | 0.219 | |||||||||
| Measles-rubella (10 dose vials) | 1 | 1 | Limited supply | Serum Institute of India | 0.48 | 0.55 | +15.6% | ||||
| Meningococcal A (10 dose vials) | 1 | 1 | Limited supply | Serum Institute of India | 0.426 | 0.6 | +40.8% | ||||
| Rotavirus | 2 | 2 | Very limited supply | GSK | 1.88 | 1.88 | 0% | ||||
| Merck | 5 | 3.5–5 | −15% | ||||||||
| Yellow fever (10 dose vials) | 1 | 2 | Very limited supply | Sanofi Pasteur | — | 1.133 | Institute Pasteur de Dakar | 0.5 | 1.132 | +126% | |
| Pneumococcal conjugate vaccinec | 2 | 2 | Very limited supply | Pfizer | 3.5 | 3.5 | 0% | ||||
| GSK | 3.5 | 3.5 | 0% | ||||||||
| Non-GAVI vaccines | |||||||||||
| BCG (20 dose vials) | 4 | 3 | Statens Serum Institute | 0.0615 | 0.153 | +149% | Intervax | 0.0466 | 0.073 | +56.7% | |
| Sanofi Pasteur | 0.13 | — | Japan BCG Lab | 0.0565 | 0.137 | +142% | |||||
| Serum Institute of India | — | 0.065 | |||||||||
| DT (10 dose vials) | 2 | 2 | Intervax | 0.0585 | 0.1195 | +104% | |||||
| PT Biofarma | 0.04 | — | |||||||||
| SII | — | 0.115 | |||||||||
| DTP (10 dose vials) | 3 | 1 | Sanofi Pasteur | 0.09 | — | PT Biofarma | 0.066 | 0.197 | +198% | ||
| Serum Institute of India | 0.09 | — | |||||||||
| Td (10 dose vials) | 2 | 3 | Intervax | 0.048 | 0.117 | +144% | |||||
| Serum Institute of India | 0.046 | 0.11 | +139% | ||||||||
| BioFarma | — | 0.1 | |||||||||
| TT (10 dose vials) | 3 | 4 | Intervax | 0.0375 | 0.093 | +148% | |||||
| Serum Institute of India | 0.038 | 0.077 | +103% | ||||||||
| Shanta | — | 0.08 | |||||||||
| Biological E | — | 0.07 | |||||||||
| PT biofarma | 0.034 | — | |||||||||
| Hepatitis B (10 dose vials) | 2 | 2 | Crucell | 0.32 | 0.16 | −50% | LG life sciences | 0.31 | 0.173 | −44% | |
| Measles-mumps-rubella (10 dose vials) | 1 | 1 | GSK | 1.85–2.5 | — | Serum Institute of India | — | 1.025 | |||
| tOPV (10 dose vials) | 2 | 2 | GSK | 0.102 | 0.18 | +76% | |||||
| Sanofi Pasteur | 0.0856 | 0.205 | +139% | ||||||||
Note. —,
vaccine not supplied by this manufacturer.
a
Source http://www.unicef.org/supply/files/Product_Menu_August_2014.pdf.
b
Or date of first GAVI purchase.
c
Price fixed via Advance Market Commitment.
d
Price increases were calculated using average price when the price/dose was provided as a range.